Jochen Rößler

ORCID: 0000-0003-4022-4917
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Vascular Malformations and Hemangiomas
  • Neuroblastoma Research and Treatments
  • Cancer, Hypoxia, and Metabolism
  • Vascular Tumors and Angiosarcomas
  • Vascular Malformations Diagnosis and Treatment
  • Childhood Cancer Survivors' Quality of Life
  • Tumors and Oncological Cases
  • Sarcoma Diagnosis and Treatment
  • Angiogenesis and VEGF in Cancer
  • Lymphatic System and Diseases
  • Acute Lymphoblastic Leukemia research
  • CAR-T cell therapy research
  • RNA Interference and Gene Delivery
  • Congenital Heart Disease Studies
  • Glioma Diagnosis and Treatment
  • Vascular anomalies and interventions
  • Vascular Anomalies and Treatments
  • Family Support in Illness
  • Palliative Care and End-of-Life Issues
  • Central Venous Catheters and Hemodialysis
  • Congenital Diaphragmatic Hernia Studies
  • Herpesvirus Infections and Treatments
  • Cardiac Valve Diseases and Treatments
  • Virus-based gene therapy research
  • Neonatal Respiratory Health Research

University of Freiburg
2013-2025

University Hospital of Bern
2019-2025

University of Bern
2020-2025

University of Rostock
2024

Novartis (Switzerland)
2024

Inserm
2023-2024

University Children’s Hospital Bern
2020-2023

University Medical Center Freiburg
2012-2022

University Medical Center of the Johannes Gutenberg University Mainz
2021

Johannes Gutenberg University Mainz
2021

Medulloblastoma is the most common brain tumour in children; using whole-genome sequencing of samples authors show that clinically challenging Group 3 and 4 tumours can be tetraploid, reveal expression first medulloblastoma fusion genes identified. malignant children. Four papers published 2 August 2012 issue Nature use other techniques to produce a detailed picture genetics genomics this condition. Notable findings include identification recurrent mutations not previously implicated...

10.1038/nature11284 article EN cc-by-nc-sa Nature 2012-07-24
Dominik Sturm Brent A. Orr Umut H. Toprak Volker Hovestadt David Jones and 95 more David Capper Martin Sill Ivo Buchhalter Paul A. Northcott Irina Leis Marina Ryzhova Christian Koelsche Elke Pfaff Sariah J. Allen Gnanaprakash Balasubramanian Barbara C. Worst Kristian W. Pajtler Sebastian Brabetz Pascal D. Johann Felix Sahm Jüri Reimand Alan Mackay Diana Carvalho Marc Remke Joanna J. Phillips Arie Perry Cynthia Cowdrey Rachid Drissi Maryam Fouladi Felice Giangaspero Maria Łastowska Wiesława Grajkowska Wolfram Scheurlen Torsten Pietsch Christian Hagel Johannes Gojo Daniela Lötsch Walter Berger Irene Slavc Christine Haberler Anne Jouvet Stefan Holm Silvia Höfer Marco Prinz Catherine Keohane Iris Fried Christian Mawrin David Scheie Bret C. Mobley Matthew Schniederjan Mariarita Santi Anna Maria Buccoliero Sonika Dahiya Christof M. Kramm André O. von Bueren Katja von Hoff Stefan Rutkowski Christel Herold‐Mende Michael C. Frühwald Till Milde Martin Hasselblatt Pieter Wesseling Jochen Rößler Ulrich Schüller Martin Ebinger Jens Schittenhelm Stephan Frank Rainer Grobholz István Vajtai Volkmar Hans Reinhard Schneppenheim Karel Zitterbart V. Peter Collins Eleonora Aronica Pascale Varlet Stéphanie Puget Christelle Dufour Jacques Grill Dominique Figarella‐Branger Marietta Wolter Martin U. Schuhmann Tarek Shalaby Michael Grotzer Timothy Van Meter Camelia-Maria Monoranu Jörg Felsberg Guido Reifenberger Matija Snuderl Lynn Ann Forrester Jan Köster Rogier Versteeg Richard Volckmann Peter van Sluis Stephan Wolf Tom Mikkelsen Amar Gajjar Kenneth Aldape Andrew S. Moore Michael D. Taylor Chris Jones

10.1016/j.cell.2016.01.015 article EN publisher-specific-oa Cell 2016-02-01

Detection of lymphatic endothelal cells (LECs) has been problematic because the lack specific markers. The homeobox transcription factor Prox1 is expressed in LECs murine and avian embryos. We have studied expression human tissues with immunofluorescence. In 19-wk-old fetuses, vascular endothelial growth receptor-3 (VEGFR-3) are coexpressed trunks capillaries. located nucleus, its mutually exclusive that blood marker PAL-E. a constitutive found healthy adults lymphedema patients. Blood...

10.1096/fj.01-1010fje article EN The FASEB Journal 2002-06-07

Purpose Currently, a routine bone marrow biopsy (BMB) is performed to detect (BM) involvement in pediatric Hodgkin's lymphoma (HL) stage greater than IIA. [ 18 F]fluorodeoxyglucose positron emission tomography (FDG-PET) increasingly used for the initial staging of HL. The value using FDG-PET BM has not been sufficiently defined. We compared results BMBs and diagnosis large group with Patients Methods 175 patients newly diagnosed classical HL IIA was determined by BMB, FDG-PET, chest computed...

10.1200/jco.2010.32.4996 article EN Journal of Clinical Oncology 2011-08-09

Objectives This cross-sectional study assessed psychological adjustment and health-related quality of life (HRQOL) in children adolescents with congenital or acquired facial differences identified potential predictors adjustment. Methods Data were obtained from 88 children, ages 9 months to 16 years, by means parent questionnaires (n = 86) standardized interviews ≥7 years old 31). Evaluation measures included the Child Behavior Checklist (CBCL), KIDSCREEN-27, TNO-AZL Preschool Quality Life...

10.1093/jpepsy/jss106 article EN Journal of Pediatric Psychology 2012-11-20

Lymphatic malformations (LM) are characterized by the overgrowth of lymphatic vessels during pre- and postnatal development. Macrocystic, microcystic combined forms LM known. The cysts lined endothelial cells (LECs). Resection sclerotherapy most common treatment methods. Recent studies performed on specimens in United States America have identified activating mutations phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) gene LM. However, whole tissue but not...

10.1371/journal.pone.0200343 article EN cc-by PLoS ONE 2018-07-09

PURPOSE Outcomes for children with relapsed and refractory high-risk neuroblastoma (RR-HRNB) remain dismal. The BEACON Neuroblastoma trial (EudraCT 2012-000072-42) evaluated three backbone chemotherapy regimens the addition of antiangiogenic agent bevacizumab (B). MATERIALS AND METHODS Patients age 1-21 years RR-HRNB adequate organ function performance status were randomly assigned in a 3 × 2 factorial design to temozolomide (T), irinotecan-temozolomide (IT), or topotecan-temozolomide (TTo)...

10.1200/jco.23.00458 article EN cc-by Journal of Clinical Oncology 2024-01-08

Abstract Objectives Clinical studies have shown low toxicity and a favorable safety profile for sirolimus in vascular anomalies. Here, we describe severe adverse events (SAEs) observed during “off‐label use” Methods We performed retrospective, multicenter chart review SAEs “off‐label” therapy anomalies analyzed these cases by predesigned workflow. Results identified 17 14 patients diagnosed with generalized lymphatic anomaly ( n = 4), Gorham–Stout disease 2), central conducting 1),...

10.1002/pbc.28936 article EN Pediatric Blood & Cancer 2021-02-13

Lymphangiomas are neoplasias of childhood. Their etiology is unknown and a causal therapy does not exist. The recent discovery highly specific markers for lymphatic endothelial cells (LECs) has permitted their isolation characterization, but expression levels stability molecular on LECs from healthy lymphangioma tissues have been studied yet. We addressed this problem by profiling normal dermis two children suffering lymphangioma, also compared them with blood (BECs) umbilical vein, aorta...

10.1186/1471-2407-7-105 article EN cc-by BMC Cancer 2007-06-21

Abstract Background Ulceration is a frequent complication of proliferating haemangioma. Methods Four patients with ulcerated hemangioma aged 2, 4, 5 months and weeks were treated 2 mg/kg KG propranolol. Results Efficacy safety propranolol excellent in all four cases. Conclusions Propranolol may be the first‐choice therapy for

10.1111/j.1468-3083.2010.03603.x article EN Journal of the European Academy of Dermatology and Venereology 2010-03-10

Abstract Purpose: Pediatric solid malignancies display important angiogenic potential, and blocking tumor angiogenesis represents a new therapeutic approach for these patients. Recent studies have evidenced rare circulating cells with endothelial features contributing to neovascularization shown the pivotal role of bone marrow–derived (BMD) progenitor in metastatic disease progression. We measured patients pediatric as prerequisite clinical trials antiangiogenic therapy. Patients Methods:...

10.1158/1078-0432.ccr-08-2363 article EN Clinical Cancer Research 2009-07-15

Tumor angiogenesis in childhood neuroblastoma is an important prognostic factor suggesting a potential role for antiangiogenic agents the treatment of high-risk disease. Within KidsCancerKinome project, we evaluated new oral selective pan-VEGFR tyrosine kinase inhibitor axitinib (AG-013736) against cell lines and subcutaneous orthotopic xenograft model IGR-N91 derived from primary bone marrow metastasis. Axitinib reduced proliferation dose-dependent manner with IC(50) doses between 274...

10.1002/ijc.25611 article EN International Journal of Cancer 2010-08-16

Paragangliomas and pheochromocytomas are genetically heterogeneous diseases. The purpose of this study was to determine the sensitivity specificity PET with 3,4-dihydroxy-6-<sup>18</sup>F-fluoro-L-phenylalanin (<sup>18</sup>F-DOPA) for detection staging pheochromocytomas/paragangliomas. Furthermore, we assessed whether genotypes paragangliomas correlate uptake <sup>18</sup>F-DOPA. <b>Methods:</b> We retrospectively analyzed 101 consecutive patients who underwent <sup>18</sup>F-DOPA or PET/CT...

10.2967/jnumed.111.101303 article EN Journal of Nuclear Medicine 2012-07-26

Abstract Background Outcome of relapsed disease localized rhabdomyosarcoma remains poor. An individual treatment approach considering the initial systemic and risk group was included in Cooperative Weichteilsarkom Studiengruppe (CWS) Guidance. Methods Second‐line chemotherapy (sCHT) ACCTTIVE based on anthracyclines (adriamycin, carboplatin, cyclophosphamide, topotecan, vincristine, etoposide) recommended for patients with low‐ (LR), standard‐ (SR), high‐risk (HR) after without...

10.1002/pbc.30363 article EN cc-by-nc-nd Pediatric Blood & Cancer 2023-04-17

Objective: VASCERN (https://vascern.eu/) is the European Reference Network for Rare Multisystemic Vascular Diseases. VASCERN-VASCA working group within that focuses on study of vascular anomalies. One objectives this to establish patient pathways guide physicians toward efficient diagnostic and management measures. The pathway presented here focused capillary malformations (CMs). Methods: Nominal Group Technique, a structured variation small discussion was used. Two facilitators were...

10.1097/jova.0000000000000102 article EN cc-by-nc-nd Journal of Vascular Anomalies 2025-02-21
Coming Soon ...